Initial experience with everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with acute myocardial infarction: a propensity-matched comparison to metallic drug eluting stents 18-month follow-up of the BVS STEMI first study

Serruys PW., 2009, A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods., Lancet., 373, 897, 10.1016/S0140-6736(09)60325-1

Serruys PW., 2010, Evaluation of the second generation of a bioresorbable everolimus drug-eluting vascular scaffold for treatment of de novo coronary artery stenosis: six-month clinical and imaging outcomes., Circulation., 122, 2301, 10.1161/CIRCULATIONAHA.110.970772

Diletti R., 2011, 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm., J Am Coll Cardiol., 58, 258, 10.1016/j.jacc.2011.02.052

Serruys PW., 2015, A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by de-novo native coronary artery lesions (ABSORB II): an interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial., Lancet., 385, 43, 10.1016/S0140-6736(14)61455-0

Brugaletta S., 2012, Circumferential evaluation of the neointima by optical coherence tomography after ABSORB bioresorbable vascular scaffold implantation: can the scaffold cap the plaque?, Atherosclerosis., 221, 106, 10.1016/j.atherosclerosis.2011.12.008

Bourantas CV., 2015, Bioresorbable vascular scaffold treatment induces the formation of neointimal cap that seals the underlying plaque without compromising the luminal dimensions: a concept based on serial optical coherence tomography data., EuroIntervention., 11, 746, 10.4244/EIJY14M10_06

Diletti R., 2014, Percutaneous coronary interventions during ST-segment elevation myocardial infarction: current status and future perspectives., EuroIntervention., 10 Suppl T, T13, 10.4244/EIJV10STA4

Farb A., 1996, Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death., Circulation., 93, 1354, 10.1161/01.CIR.93.7.1354

Diletti R., 2013, Clinical and intravascular imaging outcomes at 1 and 2 years after implantation of absorb everolimus eluting bioresorbable vascular scaffolds in small vessels. Late lumen enlargement: does bioresorption matter with small vessel size? Insight from the ABSORB cohort B trial., Heart., 99, 98, 10.1136/heartjnl-2012-302598

Serruys PW., 2011, Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes., J Am Coll Cardiol., 58, 1578, 10.1016/j.jacc.2011.05.050

Diletti R., 2014, Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study., Eur Heart J., 35, 777, 10.1093/eurheartj/eht546

Kocka V., 2014, Bioresorbable vascular scaffolds in acute ST-segment elevation myocardial infarction: a prospective multicentre study ‘Prague 19’., Eur Heart J., 35, 787, 10.1093/eurheartj/eht545

Brugaletta S., 2015, Absorb bioresorbable vascular scaffold versus everolimus-eluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: the BVS-EXAMINATION Study (bioresorbable vascular scaffold-a clinical evaluation of everolimus eluting coronary stents in the treatment of patients with ST-segment elevation myocardial infarction)., JACC Cardiovasc Interv., 8, 189, 10.1016/j.jcin.2014.10.005

Onuma Y., 2011, Bioresorbable scaffold: the advent of a new era in percutaneous coronary and peripheral revascularization?, Circulation., 123, 779, 10.1161/CIRCULATIONAHA.110.971606

Onuma Y., 2010, Intracoronary optical coherence tomography and histology at 1 month and 2, 3, and 4 years after implantation of everolimus-eluting bioresorbable vascular scaffolds in a porcine coronary artery model: an attempt to decipher the human optical coherence tomography images in the ABSORB trial., Circulation., 122, 2288, 10.1161/CIRCULATIONAHA.109.921528

Sianos G., 2007, Angiographic stent thrombosis after routine use of drug-eluting stents in ST-segment elevation myocardial infarction: the importance of thrombus burden., J Am Coll Cardiol., 50, 573, 10.1016/j.jacc.2007.04.059

Gibson CM., 2001, Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy., Circulation., 103, 2550, 10.1161/01.CIR.103.21.2550

Cutlip DE., 2007, Clinical end points in coronary stent trials: a case for standardized definitions., Circulation., 115, 2344, 10.1161/CIRCULATIONAHA.106.685313

Austin PC., 2006, A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use., Stat Med., 25, 2084, 10.1002/sim.2328

Jolly SS., 2015, Randomized trial of primary PCI with or without routine manual thrombectomy., N Engl J Med., 372, 1389, 10.1056/NEJMoa1415098

Fröbert O., 2013, Thrombus aspiration during ST-segment elevation myocardial infarction., N Engl J Med., 369, 1587, 10.1056/NEJMoa1308789

Tamburino C., 2015, Contemporary practice and technical aspects in coronary intervention with bioresorbable scaffolds: a European perspective., EuroIntervention., 11, 45, 10.4244/EIJY15M01_05

Puricel S., 2016, Bioresorbable Coronary Scaffold Thrombosis: Multicenter Comprehensive Analysis of Clinical Presentation, Mechanisms, and Predictors., J Am Coll Cardiol., 67, 921, 10.1016/j.jacc.2015.12.019

Sabate M., 2016, Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with ST-segment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial., Eur Heart J., 37, 229, 10.1093/eurheartj/ehv500